Get the Stockscreener App
37.73
1.42%
0.53
After Hours:
38.15
0.42
+1.11%
Agios Pharmaceuticals Inc stock is traded at $37.73, with a volume of 590.94K.
It is up +1.42% in the last 24 hours and up +12.73% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$37.20
Open:
$37.54
24h Volume:
590.94K
Relative Volume:
1.00
Market Cap:
$2.19B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.3213
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-4.87%
1M Performance:
+12.73%
6M Performance:
+11.86%
1Y Performance:
-20.45%
1-Day Range:
$37.10
$38.12
1-Week Range:
$37.09
$40.98
52-Week Range:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
37.73 | 2.15B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Intrahepatic Cholangiocarcinoma Market: Epidemiology, - openPR.com
Live Scanner Shows Breakout on Agios Pharmaceuticals Inc.Technical Stock Breakout Predictions Signal Entry Points - metal.it
When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
What is Agios Pharmaceuticals Inc. company’s growth strategyMassive wealth growth - jammulinksnews.com
What are the latest earnings results for Agios Pharmaceuticals Inc.High-yield capital appreciation - jammulinksnews.com
What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Invest confidently with data-backed picks - jammulinksnews.com
What drives Agios Pharmaceuticals Inc. stock priceRecord-breaking gains - PrintWeekIndia
What risks could impact Agios Pharmaceuticals Inc. stock performanceFree Stock Market Trend Analysis - jammulinksnews.com
What analysts say about Agios Pharmaceuticals Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
Is Agios Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional
Will Agios Pharmaceuticals Inc. stock split in the near futureJaw-dropping returns - jammulinksnews.com
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Agios Pharmaceuticals Inc - GuruFocus
Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com
Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus
Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus
Agios Pharmaceuticals price target lowered to $51 from $52 at BofA - TipRanks
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $51 - 富途牛牛
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
What makes Agios Pharmaceuticals Inc. stock attractive to long term investorsLow Risk Entry Points - Newser
Is Agios Pharmaceuticals Inc. stock a growth or value playFree Daily Stock Market Updates - Newser
Teacher Retirement System of Texas Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
why agios pharmaceuticals inc. stock attracts strong analyst attentionSafe High Return Entry Points - Newser
What makes Agios Pharmaceuticals Inc. stock price move sharplyDaily Gain Forecast - Newser
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET - The Manila Times
Agios Pharmaceuticals to Host Conference Call on Second Quarter 2025 Financial Results and Business Highlights - Nasdaq
Rare Disease Leader Agios Sets Q2 Earnings Call: Key Updates Expected on PK Activation Therapies - Stock Titan
Public market insider buying at Extendicare (EXE) - The Globe and Mail
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $452,612.86 in Stock - Defense World
FY2025 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Jul 10 '25 |
Sale |
40.00 |
1,400 |
56,000 |
17,603 |
| Gheuens Sarah | Chief Medical Officer |
Jul 09 '25 |
Option Exercise |
25.01 |
11,914 |
297,969 |
73,185 |
| Gheuens Sarah | Chief Medical Officer |
Jul 09 '25 |
Sale |
37.99 |
11,914 |
452,601 |
61,271 |
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):